TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31561030

Group type: EXPERIMENTAL
Intervention: ICD implanted in 1.5PP patients
Number of subjects: 3889

Group type: COMPARATOR
Intervention: 1.5PP patients without ICD
Number of subjects: 3889

Group type: EXPERIMENTAL
Intervention: 1.5PP patients
Number of subjects: 3889
Study: 31561250

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 3384
Study: 31561395

Group type: EXPERIMENTAL
Intervention: Selective head cooling
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-cooling group (late presentation after 6 hours of birth)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-cooling group
Number of subjects: 30
Study: 31561871

Group type: EXPERIMENTAL
Intervention: Unstimulated IVF cycles (natural cycles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stimulated IVF cycles (gonadotropin-stimulated cycles)
Number of subjects: 0
Study: 31562145

Group type: EXPERIMENTAL
Intervention: Oral medications
Number of subjects: 11500

Group type: EXPERIMENTAL
Intervention: Prostate surgery
Number of subjects: 11500
Study: 31562504

Group type: EXPERIMENTAL
Intervention: Maternal RBC folate in early pregnancy
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Cord plasma UMFA
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Maternal RBC folate concentrations in the highest quartile and serum vitamin B-12 concentrations in the lowest quartile
Number of subjects: 368
Study: 31562530

Group type: EXPERIMENTAL
Intervention: Intranasal inoculation with nonattenuated, wild-type Bordetella pertussis strain B1917; dose escalated from 10^3 to 10^5 colony-forming units.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Azithromycin administered from Day 14.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Assessment of antipertussis toxin IgG seroconversion.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nasal wash for colonization detection.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Environmental sampling for Bordetella pertussis shedding.
Number of subjects: 34
Study: 31562705

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 2458

Group type: EXPERIMENTAL
Intervention: Medicare participants
Number of subjects: 2458

Group type: COMPARATOR
Intervention: Non-Medicare (NM) participants
Number of subjects: 2458
Study: 31562873

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training and physical therapy
Number of subjects: 182
Study: 31562874

Group type: EXPERIMENTAL
Intervention: Fact-CAD scale
Number of subjects: 250
Study: 31563412

Group type: EXPERIMENTAL
Intervention: Cetuximab-RT plus avelumab (10 mg/kg Q2W + 4 months maintenance)
Number of subjects: 10
Study: 31563517

Group type: EXPERIMENTAL
Intervention: Pegilodecakin plus pembrolizumab
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Pegilodecakin plus nivolumab
Number of subjects: 111
Study: 31563637

Group type: EXPERIMENTAL
Intervention: Surgical pleurodesis
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Air travel
Number of subjects: 94
Study: 31563683

Group type: EXPERIMENTAL
Intervention: low iFR-high FFR group
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: high iFR-low FFR group
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: low iFR-low FFR group
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: high iFR-high FFR group
Number of subjects: 596
Study: 31563688

Group type: EXPERIMENTAL
Intervention: Post-PCI QFR
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Post-PCI QFR ≤0.89
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Post-PCI QFR best cutoff
Number of subjects: 602
Study: 31563880

Group type: EXPERIMENTAL
Intervention: Regional anesthesia (RA) administered within 7 days after injury
Number of subjects: 358

Group type: COMPARATOR
Intervention: No regional anesthesia (RA) administered
Number of subjects: 358
Study: 31564038

Group type: EXPERIMENTAL
Intervention: Whole-body magnetic resonance imaging (MRI)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional imaging (computed tomography and somatostatin receptor scintigraphy)
Number of subjects: 31
Study: 31564189

Group type: EXPERIMENTAL
Intervention: Adverse pregnancy outcomes
Number of subjects: 4484

Group type: EXPERIMENTAL
Intervention: Any hypertensive disorders of pregnancy
Number of subjects: 4484

Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 4484

Group type: EXPERIMENTAL
Intervention: Preterm birth
Number of subjects: 4484

Group type: EXPERIMENTAL
Intervention: Indicated preterm birth and hypertensive disorders of pregnancy
Number of subjects: 4484

Group type: COMPARATOR
Intervention: No adverse pregnancy outcomes
Number of subjects: 4484
Study: 31564243

Group type: COMPARATOR
Intervention: Mechanical thrombectomy
Number of subjects: 7
Study: 31564440

Group type: EXPERIMENTAL
Intervention: Hyperpolarized pyruvate MRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RNA sequencing data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein expression analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted DNA sequencing for actionable mutations
Number of subjects: 0
Study: 31564556

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin)
Number of subjects: 137
Study: 31564849

Group type: EXPERIMENTAL
Intervention: Smokers with COPD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-COPD smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 0
Study: 31565406

Group type: EXPERIMENTAL
Intervention: 1X incentive (50 Taka)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: 2X incentive (100 Taka)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: 5000 UGX incentive
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: 10,000 UGX incentive
Number of subjects: 614

Group type: COMPARATOR
Intervention: No incentive (Control)
Number of subjects: 614
Study: 31566105

Group type: EXPERIMENTAL
Intervention: Patients with acute myocardial infarction (MI)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Patients with low-density lipoprotein cholesterol ≥1 g/L
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Patients with MI
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Patients with low-density lipoprotein cholesterol concentration
Number of subjects: 202
Study: 31566148

Group type: EXPERIMENTAL
Intervention: DASH diet adherence (measured by DASH diet score - DASH-DS)
Number of subjects: 3051

Group type: EXPERIMENTAL
Intervention: Higher DASH-DS
Number of subjects: 3051
Study: 31566438

Group type: EXPERIMENTAL
Intervention: CCR2 antagonist (CCR2A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined CCR2 antagonist (CCR2A) and angiotensin-converting enzyme inhibitor (ACEi)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor (ACEi)
Number of subjects: 0
Study: 31566575

Group type: EXPERIMENTAL
Intervention: Treated patients
Number of subjects: 997

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Patients achieving sustained virological response at 24 weeks (SVR24)
Number of subjects: 997

Group type: COMPARATOR
Intervention: Patients not achieving SVR24
Number of subjects: 997
Study: 31566744

Group type: EXPERIMENTAL
Intervention: Cryoablation of the posterior nasal nerve (PNN)
Number of subjects: 98
Study: 31567024

Group type: EXPERIMENTAL
Intervention: Stellarex drug-coated balloon (DCB)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Uncoated percutaneous transluminal angioplasty (PTA)
Number of subjects: 589
Study: 31567180

Group type: EXPERIMENTAL
Intervention: Pancreatic duct occlusion (PDO) with neoprene-based glue
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pancreaticojejunal anastomosis (PJA)
Number of subjects: 100
Study: 31567396

Group type: EXPERIMENTAL
Intervention: Intraoperative SHP block
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-SHP
Number of subjects: 60
Study: 31567472

Group type: EXPERIMENTAL
Intervention: Kaolin-maximum amplitude (K-MA)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Kaolin-maximum rate of thrombus generation using G (K-MRTGG)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Functional fibrinogen-maximum amplitude (FF-MA)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Functional fibrinogen-maximum rate of thrombus generation using G (FF-MRTGG)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: K-MRTGG
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: K-MA
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: FF-MRTGG
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: FF-MA
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: TEG parameters derived from Kaolin and functional fibrinogen assays
Number of subjects: 98
Study: 31567475

Group type: EXPERIMENTAL
Intervention: Patients without typical chest pain
Number of subjects: 2922

Group type: EXPERIMENTAL
Intervention: Presentation without chest pain
Number of subjects: 2922
Study: 31567524

Group type: EXPERIMENTAL
Intervention: Elevated kidney biomarkers at ICU discharge
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Kidney injury biomarkers at discharge
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Subclinical kidney injury classification
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Acute kidney injury during ICU stay
Number of subjects: 1207
Study: 31567573

Group type: EXPERIMENTAL
Intervention: Intra-operative fentanyl dosing
Number of subjects: 363
Study: 31567634

Group type: EXPERIMENTAL
Intervention: Left atrial appendage excision during cardiac surgery
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Blood samples collected before surgery and at 6 and 12 months' follow-up
Number of subjects: 150
Study: 31568240

Group type: EXPERIMENTAL
Intervention: Fluid overload (≥ 20% on day 3)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Acute kidney injury (defined by creatinine or urine output on day 3)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Fluid overload and acute kidney injury combined
Number of subjects: 149
Study: 31568271

Group type: EXPERIMENTAL
Intervention: C-methionine PET (MET PET)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluorine-18 fluorodeoxyglucose PET/computed tomography (FDG PET)
Number of subjects: 30
Study: 31568620

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) therapy
Number of subjects: 2091
Study: 31568962

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4465

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 4465
Study: 31570103

Group type: EXPERIMENTAL
Intervention: Current-metformin-users
Number of subjects: 0

Group type: COMPARATOR
Intervention: Never-metformin-users
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prediabetic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normoglycemic patients (NG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prediabetic never-metformin-users
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflammatory tone and leptin to adiponectin ratio
Number of subjects: 0
Study: 31570255

Group type: EXPERIMENTAL
Intervention: NIRS-intravascular ultrasound imaging
Number of subjects: 1563
Study: 31570488

Group type: EXPERIMENTAL
Intervention: Eltrombopag initiated at 50 mg/day, maximum 150 mg/day
Number of subjects: 18
Study: 31570517

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg daily on days 4 to 10 of each 14-day cycle with mFOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Regorafenib plus FOLFOX
Number of subjects: 36
Study: 31570633

Group type: EXPERIMENTAL
Intervention: hs-cTnI-VITROS
Number of subjects: 1231

Group type: COMPARATOR
Intervention: hs-cTnT-Elecsys
Number of subjects: 1231

Group type: COMPARATOR
Intervention: hs-cTnI-Architect
Number of subjects: 1231

Group type: COMPARATOR
Intervention: hs-cTnI-Centaur
Number of subjects: 1231

Group type: COMPARATOR
Intervention: hs-cTnI-Access
Number of subjects: 1231

Group type: EXPERIMENTAL
Intervention: hs-cTnI-VITROS-0/1-h algorithm
Number of subjects: 1231
Study: 31570634

Group type: EXPERIMENTAL
Intervention: hs-cTnI-Access 0/2-h algorithm
Number of subjects: 2411
Study: 31570781

Group type: EXPERIMENTAL
Intervention: G-CSF + plerixafor (G + P)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: G-CSF + plerixafor + chemotherapy (G + P + C)
Number of subjects: 313
Study: 31570822

Group type: EXPERIMENTAL
Intervention: HRDetect-high patients on adjuvant chemotherapy
Number of subjects: 254

Group type: COMPARATOR
Intervention: HRDetect-low cancers
Number of subjects: 254

Group type: COMPARATOR
Intervention: HRDetect-intermediate patients
Number of subjects: 254
Study: 31571315

Group type: EXPERIMENTAL
Intervention: 6-month physical activity intervention with activity trackers
Number of subjects: 49
Study: 31571945

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole modified release-based therapy (DACM)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Lansoprazole-based therapy (Control)
Number of subjects: 202
Study: 31571977

Group type: EXPERIMENTAL
Intervention: Tramadol (2 mg/kg bolus)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 31572236

Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paroxetine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sertraline hydrochloride
Number of subjects: 0
Study: 31572288

Group type: EXPERIMENTAL
Intervention: Simulation-based training for rapid evaluation and management of acute stroke; details on dosage and duration not available.
Number of subjects: 0
Study: 31572702

Group type: EXPERIMENTAL
Intervention: Neighborhood perception
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 0
Study: 31573078

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab plus standard induction chemotherapy for DLBCL or FL for 4-7 cycles, and/or every 2 months maintenance monotherapy for FL for 6-12 cycles.
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab
Number of subjects: 140
Study: 31573746

Group type: EXPERIMENTAL
Intervention: Response-adapted therapy with rituximab, bendamustine, mitoxantrone, and dexamethasone (RBMD)
Number of subjects: 60
Study: 31573933

Group type: EXPERIMENTAL
Intervention: Pharmacist-led, technology-enabled intervention using an innovative dashboard system
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1600
Study: 31573931

Group type: EXPERIMENTAL
Intervention: Ovarian tissue autograft
Number of subjects: 38
Study: 31573977

Group type: EXPERIMENTAL
Intervention: Higher relative abundance of polyunsaturated triacylglycerols (TAGs)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Lower abundance of C16-C20 acylcarnitines (ACs)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Unsaturated free fatty acids and phosphatidylethanolamines
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: C16-C20 ACs and short-low-double-bond TAGs by categories of albuminuria
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Renal expression of acetyl-CoA carboxylase-encoding gene (ACACA)
Number of subjects: 92
Study: 31573980

Group type: EXPERIMENTAL
Intervention: rosuvastatin (20 mg/d × 28 days)
Number of subjects: 18
Study: 31574809

Group type: EXPERIMENTAL
Intervention: OAK device
Number of subjects: 183

Group type: COMPARATOR
Intervention: CDC algorithm
Number of subjects: 183
Study: 31574863

Group type: EXPERIMENTAL
Intervention: Laser meridian massage (3 times weekly for 4 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no laser meridian massage)
Number of subjects: 15
Study: 31575518

Group type: EXPERIMENTAL
Intervention: DCB angioplasty
Number of subjects: 1343

Group type: EXPERIMENTAL
Intervention: Paclitaxel or nonpaclitaxel reinterventions
Number of subjects: 1343

Group type: EXPERIMENTAL
Intervention: Baseline covariates predicting mortality
Number of subjects: 1343
Study: 31575668

Group type: EXPERIMENTAL
Intervention: APACHE II
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: SAPS II
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: SOFA
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: ATN-ISI
Number of subjects: 189
Study: 31575939

Group type: EXPERIMENTAL
Intervention: Intravenous enzyme replacement therapy (IV-ERT) for 2 years
Number of subjects: 10
Study: 31576162

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen + 100 mg caffeine
Number of subjects: 635

Group type: COMPARATOR
Intervention: 400 mg ibuprofen
Number of subjects: 635

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study: 31576173

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 171
Study: 31576181

Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac joint fusion (SIJF) using triangular titanium implants (TTI)
Number of subjects: 103
Study: 31576609

Group type: EXPERIMENTAL
Intervention: In-depth interviews with patients and family caregivers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home environment assessment
Number of subjects: 0
Study: 31576684

Group type: EXPERIMENTAL
Intervention: BLS-M07 (500 mg, 1,000 mg, and 1,500 mg administered orally, 5 times a week on weeks 1, 2, 4, and 8)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: BLS-M07 (1,000 mg administered orally in phase 2a)
Number of subjects: 19
Study: 31576773

Group type: EXPERIMENTAL
Intervention: Face-to-face visit to the family doctor
Number of subjects: 336

Group type: COMPARATOR
Intervention: Transport by emergency medical services
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Lack of awareness of stroke symptoms
Number of subjects: 336
Study: 31577153

Group type: EXPERIMENTAL
Intervention: Lung recruitment estimated by the Recruitment-to-Inflation Ratio
Number of subjects: 0
Study: 31577217

Group type: EXPERIMENTAL
Intervention: p-axSpA
Number of subjects: 203

Group type: COMPARATOR
Intervention: axSpA
Number of subjects: 203
Study: 31577664

Group type: EXPERIMENTAL
Intervention: Fluorescent angiography with indocyanine green
Number of subjects: 51

Group type: COMPARATOR
Intervention: Clinical evaluation (control group)
Number of subjects: 51
Study: 31577715

Group type: EXPERIMENTAL
Intervention: Higher AVF luminal pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assisted AVF maturation
Number of subjects: 0
Study: 31577771

Group type: EXPERIMENTAL
Intervention: Positive PSA results
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Negative PSA results
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Patient management after positive PSA value
Number of subjects: 1653
Study: 31577804

Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 2087

Group type: COMPARATOR
Intervention: No Tracheostomy
Number of subjects: 2087
Study: 31578012

Group type: EXPERIMENTAL
Intervention: Rivaroxaban treatment in patients with prior ischemic stroke/TIA
Number of subjects: 9578

Group type: COMPARATOR
Intervention: Rivaroxaban treatment in patients without prior ischemic stroke/TIA
Number of subjects: 9578
Study: 31578082

Group type: EXPERIMENTAL
Intervention: Evinacumab
Number of subjects: 9
Study: 31578311

Group type: EXPERIMENTAL
Intervention: Gene-corrected autologous cell therapy (transplanted epidermal sheets measuring 5 × 7 cm)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Gene-corrected autologous cell therapy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (untreated wounds)
Number of subjects: 7
Study: 31578700

Group type: EXPERIMENTAL
Intervention: Practical training tutored by an expert
Number of subjects: 172

Group type: COMPARATOR
Intervention: Direct access to DUS examination without practical training
Number of subjects: 172
Study: 31579027

Group type: EXPERIMENTAL
Intervention: BTG-002814 (100 mg vandetanib) delivered transarterially, 7 to 21 days before surgery
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: BTG-002814 (100 mg vandetanib)
Number of subjects: 3
Study: 31579047

Group type: EXPERIMENTAL
Intervention: Seismocardiograph (SCG) during breath-holding
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ballistocardiograph (BCG) during breath-holding
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Seismocardiograph (SCG) during spontaneous respiration following apnea
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ratio of iK of diastole to systole during restoration of respiration
Number of subjects: 43
Study: 31579106

Group type: EXPERIMENTAL
Intervention: Atlas Unicompartmental Knee System Load Absorber
Number of subjects: 26
Study: 31579436

Group type: EXPERIMENTAL
Intervention: SVM model using target miRNA/reference miRNA ratio
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Principal component analysis
Number of subjects: 59
Study: 31579676

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 0
Study: 31580130

Group type: EXPERIMENTAL
Intervention: Coping self-efficacy
Number of subjects: 0
Study: 31580386

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine plus cisplatin (25 mg/m2, 37.5 mg/m2, 50 mg/m2) on days 1 and 8 of a 21-day cycle
Number of subjects: 25
Study: 31581055

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks for up to 2 years
Number of subjects: 1008
Study: 31581306

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 0
Study: 31581800

Group type: EXPERIMENTAL
Intervention: SCC DBS
Number of subjects: 28
Study: 31582135

Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 503
Study: 31582133

Group type: EXPERIMENTAL
Intervention: Stress CMR with no ischemia or late gadolinium enhancement (LGE)
Number of subjects: 2349

Group type: EXPERIMENTAL
Intervention: Stress CMR with ischemia+/LGE+
Number of subjects: 2349

Group type: EXPERIMENTAL
Intervention: Patients with ischemia and LGE both negative
Number of subjects: 2349
Study: 31582137

Group type: EXPERIMENTAL
Intervention: Motorized hyperemic pullback pressure gradients (PPGs)
Number of subjects: 117
Study: 31582202

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Hepatitis B virus (HBV) vaccination
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vaccination against all three microorganisms
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Predictors of correct vaccination
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sick leaves due to flu
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lost working days due to flu
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Hospitalizations due to flu
Number of subjects: 300